Core Insights - Generation Bio Co. is focused on developing innovative treatments for T cell-driven autoimmune diseases using a novel cell-targeted lipid nanoparticle (ctLNP) delivery system for siRNA [2][4] Business Highlights - The company aims to address limitations in current treatments for autoimmune diseases by targeting T cell pathology, with plans to announce its lead ctLNP-siRNA program strategy in mid-2025 [2][7] Financial Results - As of March 31, 2025, the company reported cash, cash equivalents, and marketable securities of $157.6 million, down from $185.2 million as of December 31, 2024 [8][11] - Research and development expenses for Q1 2025 were $15.4 million, compared to $14.3 million in Q1 2024 [8][13] - General and administrative expenses decreased to $8.8 million in Q1 2025 from $10.4 million in Q1 2024 [8][14] - The net loss for Q1 2025 was $14.8 million, or $0.22 per share, significantly improved from a net loss of $74.5 million, or $1.12 per share, in Q1 2024 [8][14]